RenovoRx, Inc. (RNXT)

RenovoRx announced its first quarter 2026 financial results and business highlights conference call for May 14th, 2026, reporting $1.1 million in revenue for the full year 2025 from RenovoCath sales. An abstract supporting the TAMP therapy platform was accepted for presentation at the 2026 ASCO Annual Meeting, and clinical data was presented at the 2026 SIR Annual Scientific Meeting. The Phase III TIGeR-PaC trial surpassed 100 randomized patients, with enrollment completion anticipated by mid-2026 and final data in 2027. RenovoRx closed an oversubscribed $10 million at-market private placement in March 2026 and secured its first Notice of Allowance for a Japanese patent covering its RenovoCath device in April 2026. The company has reported continued commercial momentum with a growing number of U.S. cancer centers integrating RenovoCath into oncology treatment programs.

There is no explicit mention of demand seasonality for RenovoRx's products and services. The company has reported growing clinical demand and commercial momentum for its RenovoCath device, with an increase in cancer center customers and repeat orders since launching commercial efforts in December 2024.

RenovoRx, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted oncology therapies and commercializing its RenovoCath device. The company operates in the Healthcare sector, combining pharmaceutical preparation manufacturing and medical device commercialization. Its primary product, RenovoCath, is designed for targeted delivery of therapeutic agents to tumor sites. The company is also evaluating intra-arterial gemcitabine (IAG) in a Phase III clinical trial for locally advanced pancreatic cancer (LAPC).

RenovoRx's commercialization efforts are primarily focused within the United States. The company has expanded its commercial footprint to include 13 cancer centers approved to purchase RenovoCath. Four of these centers were actively using the device in patients and had placed repeat orders as of August 2025. The company's corporate office is located in Mountain View, California.

RenovoRx was named to Fast Company's annual list of the World's Most Innovative Companies of 2026, ranking #10 in the medical device category. The company also reported that 2025 was its first full year of revenue following the commercial launch of RenovoCath, indicating growing adoption in cancer centers across the U.S.

RenovoRx stock ownership is a mix of institutional, retail, and individual investors. Approximately 9.09% to 16.15% of the company's stock is held by institutional investors, 3.29% by insiders, and a significant portion (80.57%) by public companies and individual investors (retail investors). Major institutional owners and shareholders include AIGH Capital Management LLC, Vanguard Group Inc, and Geode Capital Management, Llc.